Sandu Pharma: No Deviation in Use of Funds from Preferential Issues

Sandu Pharmaceuticals Limited has filed a statement of deviation and variation of funds for the quarter ended September 30, 2026. The company reported no deviation or variation in the utilization of funds raised through a preferential issue of equity shares (private placement) on March 31, 2021, amounting to ₹2,63,79,653, and another on February 28, 2022, amounting to ₹1,38,05,408. The funds were originally intended for revamping the company's capital, developing marketing infrastructure, civil work for plant and machinery, purchase of new/additional plant and machinery, working capital, investment in technologies, and general business enhancement. The Audit Committee has reviewed and approved the statement, noting no issues with fund utilization.